Jefferies Sees No Read-Through to The Medicines Company (MDCO) PCSK9 from Alnylam Setback
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
The Medicines Company Provides Progress Update on Ongoing ORION-1 Study of PCSK9si
October 5, 2016 4:35 PM EDTResults from ORION-1 interim analysis with Day 90 follow-up will be presented in Late-Breaking Clinical Trial Session at American Heart Association (AHA) meeting on November 15, 2016
The Company anticipates that top-line data from Day 180 follow-up for up to 200 patients will also be presented at the Late-Breaking Clinical Trial Session
Based on review of safety data by the Independent Data Monitoring Committee through August 26, 2016 (unblinded) and the Company through September 29, 2016 (blinded), no material safety issue and, in particular, no drug-related neuropathy, elevation of liver enzymes or changes in renal function, has been... More
